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AN ANALYSIS OF TOBACCO CESSATION QUIT AIDS AND QUIT 
ATTEMPTS FROM A NATIONAL STUDY ON TOBACCO CESSATION 
MICHAEL CHRISTOPHER HAYDU 
ABSTRACT 
Background: Since the initial report on the negative effects of smoking by the Surgeon 
General’s Advisory Committee, the components of cigarettes and tobacco smoke and the 
mechanisms by which these cause disease have been studied extensively. Despite the 
well-documented health consequences associated with tobacco use, nearly 70 million 
Americans over the age of 12 actively use tobacco products, with 57.5 million of these 
(22.1% of the U.S. population in this age range) actively smoking cigarettes. 
Understanding how nicotine addiction develops and reinforces itself is important context 
for understanding the high prevalence of quit interest among smokers and the high 
relapse rates associated with quit attempts. While the increased availability of different, 
clinically proven tobacco cessation aids should lower the barrier associated with tobacco 
abstinence, the prevalence of quit aid use still remains low among those attempting to 
quit smoking. This study examines quit interest in active smokers, the quit attempts 
attempted by current and former smokers, the prevalence of tobacco cessation aid use in 
these quit attempts, and the perceived efficacy of certain quit aids. 
Methods: This study was conducted in the Emergency Departments of ten hospitals 
nationwide by the National Association of Research Associates Programs in 2012. This 
study utilized trained research staff to enroll non-emergent patients and visitors over the 
age of 18 years old, obtaining demographical information and a detailed history of 
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tobacco use from the participant. This included such information as current tobacco use 
status, how many cigarettes were consumed during a typical day, how many times they 
had attempted to abstain from tobacco use in the past, if they had used any tobacco 
cessation aids during those quit attempts, and, if so, how effective they believed these 
aids were. Participants were also asked to rate their readiness to quit smoking and intent 
to quit smoking, markers this study used to analyze quit interest.  
Results: Of those approached, 10,303 study participants were selected for inclusion in 
this study, reporting tobacco use for longer than one month at any point in their life. 
50.5% reported current tobacco use, while 46.8% reported current abstention from 
smoking. A majority of active smokers expressed interest in initiating tobacco cessation, 
with 55.2% reporting they were ready to quit smoking, though a smaller majority (51.9%) 
of active smokers reported that they intended to quit smoking. Most smokers reported at 
least 1 quit attempt in the past, with 76.5% of former smokers reporting that they quit 
within 1 to 5 attempts. Only 30.7% of study participants reported ever using some form 
of tobacco cessation aid in previous quit attempts, with nicotine replacement therapy use 
being the most commonly reported, and with pharmacological interventions more 
commonly reported than counseling-based cessation interventions. A majority of 
participants who reported using nicotine replacement gum and lozenges (57.8% and 
49.5%, respectfully) reported that they were not helpful in aiding their cessation attempts, 
with only 30.1% of gum and 38.7% of lozenge users reporting a positive effect. 
Conclusions: The results indicated that among active smokers, smokers that reported 
smoking less (only some days or fewer cigarettes per day) were more likely to express 
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interest (readiness and intent) in initiating tobacco cessation than those that reported 
smoking more (every day or more cigarettes per day). Quit interest also appeared to be 
lowest in 18-25 year olds, with this age group also reporting the lowest proportion of quit 
attempts, a finding that differed from another national tobacco survey. The prevalence of 
quit aid use in our study was comparable to another national tobacco survey, but our 
findings for the prevalence of unassisted quit attempts did not coincide with results found 
in other studies. These results also indicated that cessation aid use increased with 
increased number of quit attempts. Though we found that former smokers were more 
likely to indicate that NRT products were helpful than active smokers were, we were 
unable to fully analyze the perceived effects of cessation aid use due to the loss of some 
of this data. In light of the limitations of this study, further study needs to be conducted to 
better understand the perceived effect of tobacco cessation aids and how this might differ 
from the efficacy values found in clinical trials. In order to make findings more 
comparable to other tobacco surveys, future studies should also be designed around clear 
and common definitions for active tobacco use and quit interest, and a focus on quit 
attempts should be modulated by some degree of recency (e.g., quit attempts made within 
the previous year or two years). 
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BACKGROUND 
The Tobacco Epidemic 
 In 1964, the Surgeon General’s Advisory Committee on Smoking Health 
published “Smoking and Health: Report of the Advisory Committee to the Surgeon 
General of the United States.” The report highlighted the impact of smoking on human 
health, including a causal link between smoking and both lung cancer and chronic 
bronchitis and reports on correlations between smoking and a number of cardiovascular 
and respiratory diseases. While it wasn’t the first public declaration of the health 
consequences of smoking in the US, which actually came in 1957, it appeared to have a 
greater impact than previous statements. In the years following the report, there was a 
noticeable increase in the public awareness of the dangers associated with tobacco use 
and the beginnings of national tobacco control (NLM, n.d.). 
 The report also instigated further research on the health effects of smoking and 
how cigarette smoke could lead to these disease states. Since the report, over 7,357 
chemical compounds have been identified in tobacco smoke (USDHHS, 2010). Of these 
chemicals, there a few families of chemicals that pose a significant health risk via 
exposure through active tobacco use or secondhand through environmental tobacco 
smoke (ETS). These families include nitrosamines, polycyclic aromatic hydrocarbons 




Table 1: Hazardous components of tobacco smoke and health risks associated with exposure. Of over 7,000 compounds found in 
tobacco smoke, those listed below have been proven to cause the corresponding effects in human and/or animal models. 
Chemical Component of Tobacco Smoke Potential Health Risk Disease Implications 
Nitrosamines     
 N-Nitrosdiethylamine (NDEA) Carcinogen Lung, Esophageal, Stomach, Liver, and Bladder Cancers 
 N-Nitrosodimethylamine (NDMA) Carcinogen Lung, Stomach, and Colorectal Cancers 
 N’-Nitrosonornicotine (NNN) Carcinogen Lung, Pancreatic, Esophageal, and Oral Cancers 
 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone 
(NNK) Carcinogen Lung Cancer 
Polycyclic Aromatic Hydrocarbons (PAHs)     
 Benzo(a)pyrene Carcinogen Lung, Breast, Cervical, and Oral Cancers 
Volatile Hydrocarbons     
 1,3-butadiene Carcinogen, Atherogenic promoter Breast and Ovarian Cancers, Cardiovascular (CV) Disease 
 Benzene Carcinogen Leukemia 
Aromatic Amines     
 2-naphthylamine Carcinogen Bladder Cancer 
 4-aminobiphenyl Carcinogen Urothelial Cancer, Bladder Cancer, and Laryngeal Cancer 
Aldehydes     
 Formaldehyde Carcinogen Nasopharyngeal Cancer and Leukemia 
 Acetaldehyde Carcinogen Lung, Oral, Throat, Stomach, Liver, and Colorectal Cancers 
 Acrolein Carcinogen, Irritant, Ciliotoxin Gingival/Oral Cancers, Respiratory Disease 
Metals     
 Arsenic Carcinogen, CV Effects Skin Cancer, CV Disease 
 Nickel Carcinogen, Respiratory Concerns Lung, Nasal Sinus, and Renal Cancers, and Chronic Bronchitis 
 Polonium-210 Carcinogen Lung Cancer 
 Cadmium Carcinogen, CV Effects, Irritant Lung and Other Cancers, CV Diseases, Respiratory Disease 
 Lead Carcinogen, CV Effects Lung and Stomach Cancer, CV Diseases 
 Chromium VI Carcinogen Lung Cancer 
Other Compounds     
 Hydrogen Cyanide (HCN) Ciliotoxin, Irritant Respiratory Disease 
 Carbon Monoxide (CO) Ciliotoxin, Hypoxia Respiratory Disease 
 Nitrogen Oxide (NO) Difficulty Breathing Respiratory Disease 
 Ammonia Ciliotoxin, Increases Addictiveness Respiratory Disease 
 Sulfur Dioxide Ciliotoxin Respiratory Disease 
 Hydrogen Sulfide Irritant Respiratory Disease 
 Nicotine Addictive Substance, Stimulant CV Disease, Substance Withdrawal Symptoms 
(Table made using research from USDHHS, 2010; USDHHS, 2014; and Cancer Research UK, 2012; 
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The Health Consequences of Smoking 
Cancer 
 One of the most recognized effects of the components of tobacco smoke has been 
the development of various cancers. Active male smokers between the ages of 35-54 are 
said to have a relative risk of 14.33 for developing lung cancer, or that they are 14.33 
times more likely to develop lung cancer than non-smokers. This risk increases with age 
and 65-74 year old smokers are 28.29 times more likely to develop lung cancer. Among 
former smokers, the relative risk drops to 4.40 at 35-54 years of age, increasing to 7.79 at 
65-74 years of age (USDHHS, 2014). The relative risk for developing any of the other 
types of cancer associated with smoking1 are less substantial though still observable, 1.74 
at 35-54 and 2.35 at 65-74 for active male smokers, compared to 1.36 and 1.49 for former 
smokers (USDHHS, 2014). Similar trends were also seen in the cancer risks for women. 
Of the components listed in Table 1, only 2-napthylamine, 4-aminobiphenyl, 
benzene, formaldehyde, arsenic, nickel, chromium VI, cadmium, and lead are said to 
have been studied sufficiently enough in human studies to establish causal linkages of 
their carcinogenic properties to human instances of cancer. Other components of tobacco 
smoke have been studied with sufficient evidence of carcinogenicity in animal models, 
but only limited human evidence has been obtained at this time (USDHHS, 2010). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 These include lip, oral, nasopharyngeal, laryngeal, esophageal, stomach, pancreatic, cervical, 
renal, bladder, liver, and colorectal cancers, as well as acute myeloid leukemia. 
 
2 Active tobacco use is defined as past-month use or use within the previous 30 days. 
3 The required warning: "Caution: Cigarette Smoking May Be Hazardous to Your Health."  
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Cancer formation does not usually occur as a direct action of the component of 
tobacco smoke, as shown in Figure 1. These components are generally either 
metabolized or transformed in a way that allows the metabolite or modified form to react 
with nucleic acids. Reacting with the nucleic acid damages the DNA, forming DNA 
adducts. Without proper repair of the DNA, the mutated state of the cell could lead to 
tumor formation. 
 Lung cancer is the second most common form of cancer among Americans and is 
the leading cause of cancer-related mortality in the United States (CDC, 2014b). Tobacco 
use has been extensively linked with the development of lung cancer, usually through the 
mutation of tumor suppressor genes. Mutations in the retinoblastoma protein (RB) gene, 
the p53 tumor suppressor gene (TP53), and the liver kinase B1 or serine/threonine kinase 
11 (LBK11/STK11) gene are common occurrences in the development of these cancers. 
RB mutations have been noted in 90% of small cell carcinomas and approximately 15% 
of non-small cell carcinomas. Mutation of the TP53 gene was found in approximately 
70% of small cell carcinomas and 50% of non-small cell carcinomas. The mutation of the 
LBK1/STK11 gene was found in nearly 35% of non-small cell carcinomas studied. 
(USDHHS, 2010). 
The activation of oncogenes is another mode of carcinogenesis in the 
development of lung cancer. The activation of the V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS) is the most commonly found, having been noted in 
approximately 40% of the adenocarcinoma precursors (USDHHS 2010). The mutation of 
the KRAS oncogene has been said to work synergistically with the inactivation of 
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p53, facilitating faster tumor growth in studied animal models (Gibbons et al., 2014). 
	  
Figure 1: Pathway for the development of cancer by tobacco smoke carcinogens. Exposure to 
cigarette smoke introduces carcinogenic and mutagenic compounds into the body. The 
metabolites of these compounds can react with nucleic acids, forming DNA adducts that, if not 
properly repaired, can cause the mutations in oncogenes and tumor suppressor genes that lead to a 
loss of normal growth control and the development of cancer. (Adapted from U.S. Department of 
Health and Human Services, 2010.) 
 Benzo(a)pyrene (B(a)P), a member of the PAH family, has been extensively 
studied in its possible link to the development of lung cancer. Once metabolized, B(a)P 
forms adducts with DNA, namely BPDE-N2-deoxyguanosine (BPDE-DNA), which has 
been found in the known mutational hotspots of TP53 and the KRAS oncogene. Nicotine 
and NNK may have an indirect effect on the development of lung cancer. Studies suggest 
that these tobacco smoke components may help keep damaged cells from being properly 
apoptosized, thereby increasing the opportunity for the development of cancer 
(USDHHS, 2010). Chromium VI has also been implicated in the development of lung 
cancer by facilitating stronger formation of DNA adducts (Cancer Research UK, 2012). 
	  6 
 The components of tobacco smoke have also been implicated in the formation of 
other cancers, with associated DNA adducts found in the larynx, oral and nasal mucosae, 
bladder, cervical tissues, breast, pancreas, and stomach. BPDE-DNA adducts have been 
found in oral mucosal, cervical, and breast cells. Adducts from 4-aminobiphenyl (4-ABP-
DNA) have been found in urothelial and oral mucosal cells and in laryngeal and bladder 
tissues. Acrolein and crotonaldehyde have also been suggested to form 1,N2-




 In addition to the cancer risk associated with tobacco use, active tobacco use and 
ETS exposure have also been linked to an increased risk of developing cardiovascular 
complications. The relative risk of developing coronary artery disease (CAD) in active 
male smokers aged 35-54 is 3.88. The relative risk of developing CAD for former 
smokers in the same age range is significantly reduced, at 1.83 (USDHHS, 2014). 
Women showed a greater risk of developing CAD from active tobacco use, but the risk of 
former smokers was similar to that of formerly smoking males. Active smokers of both 
genders showed a greater incidence of developing cerebrovascular disease and other 
vascular and heart diseases compared to non-smokers and former smokers.  
 Active tobacco use and smoke exposure is said to lead to cardiovascular disease 
states in few different ways. Oxidation or oxidative stress from the components of 
tobacco smoke components can lead to endothelial injury or dysfunction in the coronary 
and peripheral arteries. Exposure to these oxidative components can lead to a chronic 
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inflammatory state, which facilitates the atherogenic disease process by altering platelet 
and endothelial function, resulting in the formation and build up of plaque on the artery 
wall. (Godtfredsen et al., 2011) Smoking can also induce an atherogenic lipid profile by 
increasing the triglyceride (TAG) levels in blood and decreasing the amount of high-
density lipoprotein (HDL) in blood. Smoking is also known to cause insulin resistance, 
which, when combined with the chronic inflammation state, can exacerbate nephropathy 
and increase hypertensive symptoms. Lastly, smoke exposure is said by increase the risk 
of thrombosis by increasing the aggregation of platelets (USDHHS, 2010). 
 Nicotine, an important component of tobacco, has sympathomimetic effects on 
the body. The intake of nicotine increases heart rate, blood pressure, and contractility of 
the heart, as well as increasing vasoconstriction. Chronic exposure to nicotine could lead 
to endothelial dysfunction, lipid abnormalities, and insulin resistance, leading to 
cardiovascular disease states (USDHHS, 2010). 
Carbon monoxide (CO), present in tobacco smoke, is found in the blood of active 
smokers at levels 5-20 times higher than in non-smokers (USDHHS, 2010). Exposure to 
CO decreases the overall oxygen capacity of the red blood cells, leading to relative 
hypoxemia in smokers. With chronic exposure to CO, the body may compensate by 
increasing red blood cell production. An increased number of red blood cells increases 
the viscosity of the blood and leads to hypercoagulative and other vascular symptoms.  
Acrolein is a reactive member of the aldehyde family found in tobacco smoke. In 
the body, acrolein has been found to induce modifications of HDL and promote 
atherogenic plaque build up in the arteries. It can also oxidize thioredoxins, leading to 
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endothelial dysfunction and atherosclerosis. Acrolein is said to also promote clotting by 
inhibiting antithrombin activity (USDHHS, 2010). 
	  
Figure 2: Overview of the effect of cigarette smoke on cardiovascular health. Oxidants and 
particulates in cigarette smoke cause inflammation of the cardiac tissue, resulting in platelet 
aggregation and endothelial injury. These factors, combined with reduced oxygen capacity from 
increased blood levels of carbon monoxide from smoking and vasoconstriction from nicotine’s 
stimulation of the sympathetic nervous system, lead to atherogenic plaque formation, reduction in 
blood flow, and reduction in cardiac oxygen. Faced with an increased myocardial demand for 
oxygen from nicotine’s sympathetic stimulation, CAD can develop and acute cardiac events can 
occur. (Modified from U.S. Department of Health and Human Services, 2014.) 
 The metals present in tobacco smoke, like lead and cadmium, are thought to 
catalyze the oxidation of proteins in cells, facilitating endothelial dysfunction, 
detachment of the endothelial cells from blood vessel walls, and structural damage. 
Accumulation of lead and cadmium in serum has also been implicated in the 
development of CAD, hypertension, and myocardial infarction (USDHHS, 2010). 
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Respiratory Disease 
 Another documented risk associated with the use of tobacco products and 
exposure to ETS is the development of respiratory diseases. These most commonly 
include chronic obstructive pulmonary disease (COPD), which includes emphysema and 
chronic bronchitis, and asthma. In actively smoking 65-74 year old males, the relative 
risk for the development of COPD is 29.69, compared to a relative risk of 8.13 for former 
smokers of the same age. Actively smoking women of this age showed a significantly 
higher relative risk of developing COPD, 38.89, and the relative risk for former female 
smokers was also higher at this age, 15.72 (USDHHS 2014). 
 COPD is a progressive respiratory disease of chronic airflow obstruction marked 
by dyspnea, chronic productive cough, and wheezing (NHLBI, 2013). Patients with 
COPD are able to move less air into and out of the lungs due to this obstruction, and the 
reduction of available oxygen can often limit their activity. Chronic bronchitis, one type 
of COPD, is usually associated with the thickening of the bronchial walls, luminal 
narrowing, and excess mucus production into the lumen (Fischer et al., 2011). Excess 
mucus production can clog the already narrowed airway and lead to the productive cough 
associated with COPD. An inflammatory response at the mucosal surface of the lungs 
and at the submucosal glands and gland ducts may also be noted in patients with chronic 
bronchitis (USDHHS, 2014). Emphysema, another type of COPD, is associated with a 
decrease in the elastic recoil forces available to move air out of the lungs. This loss of 
elasticity occurs when the walls of the alveoli are damaged or destroyed. The destruction 
	  10 
of alveolar walls leads to the abnormal and permanent enlargement of the airspaces distal 
to the terminal bronchiole noted in patients with emphysema (Fischer et al., 2011). 
 The components of tobacco smoke have been implicated in the development of 
COPD in three ways: oxidative stress, inflammation, and protease-antiprotease 
imbalance. Exposure to tobacco smoke will increase the oxidative stress in the lungs. The 
combustion involved in the smoking of a cigarette will release reactive oxygen species 
(ROS), which are then inhaled. Introducing ROSs into the body will lead to further ROS 
production and the peroxidation of lipids (Fischer et al., 2011). The particulate matter 
found in tobacco smoke will be retained as deposits in the lung. The particulate deposits 
that form have been shown to alter the homeostasis of iron, promoting increased 
accumulation of iron in the lung (Ghio et al., 2008). As ROS production is catalyzed by 
iron, this will facilitate the production of ROS in the pulmonary system and increase 
oxidative stress. Exposure to free radicals and ROS from tobacco smoke will also 
promote senescence and apoptosis of alveolar epithelial cells. 
 Tobacco smoke and the oxidative damage it cause will trigger an inflammatory 
response in the pulmonary system associated with the recruitment of neutrophils, 
macrophages, and other inflammatory cells (Fischer et al., 2011). This inflammation 
promotes the hypersecretion of mucus and the thickening of the bronchial walls, which 
can lead to airway obstruction. 
The imbalance of proteases and antiproteases is thought to be the primary cause 
of the symptoms associated with emphysema. ROS introduced by tobacco smoke activate 
alveolar macrophages and react with endogenous antiproteases, inactivating them. The 
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subsequent inflammation leads to a build up of neutrophils and macrophages, which 
release of proteases. These proteases can cleave elastin fibers and collagen in the alveoli, 
creating damaged fragments that will perpetuate the inflammatory response and cell 
accumulation in the lungs. The resulting imbalance between protease activity and the loss 
of antiprotease activity leads to further lung damage (USDHHS, 2010). 
 
Figure 3: Pathway for the development of COPD in smokers. Reactive oxygen species from 
cigarette smoke cause oxidative stress and inflammation in the pulmonary system. The 
subsequent aggregation of neutrophils and macrophages release proteases. With antiproteases 
inactivated by the introduced ROS, these proteases cleave components of the alveolar walls, 
leading to the destruction of these walls (Emphysema) and a positive feedback of further 
inflammation. Proteases also increase mucus production, which, combined with impaired ciliary 
function from inhaled ciliotoxins and inflamed bronchial walls, facilitates chronic bronchitis. 
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The ciliotoxic components of tobacco smoke, Hydrogen Cyanide (HCN), CO, 
acrolein, ammonia, and sulfur dioxide, can also lead to the development or progression of 
respiratory disease in smokers. Exposure to these compounds can impair the function of 
the cilia lining the tracheal and bronchial mucous membranes. This reduces the ability of 
smokers and patients with COPD to clear the hypersecreted mucus that builds up in the 
airway, leading to obstruction and the productive cough associated with both COPD and 
smoking. The loss of ciliary activity could also play a role the development of cancer by 
prolonging the exposure of tobacco smoke components and particulates to the lung, 
thereby increasing the risk of DNA-adduct formation and resulting mutagenesis.  
Current Tobacco Use 
 
The release of the 1964 report of Surgeon General’s Advisory Committee on the 
health consequences of smoking publically acknowledged and announced the health risks 
involved with smoking. This acknowledgement, in combination with the increased 
tobacco control that followed, sparked a decline in the prevalence of active smoking in 
the United States. In 1965, approximately 42.4% of Americans over the age of 18 
reported currently using tobacco products. Forty years later, that percentage had dropped 
to an estimated 20.9% of the adult population (CDC, 2013b). The decline in smoking 
following the 1964 report has translated to the prevention of nearly 795,000 smoking-
related deaths (NIH, 2012). Despite the well-documented risks involved with smoking 
and the benefits of tobacco cessation, however, a substantial amount of the population 
still uses tobacco products. 
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According to the 2012 National Survey on Drug Use and Health (NSDUH) by the 
U.S. Department of Health and Human Services (USDHHS), approximately 69.5 million 
Americans over the age of 12 actively use tobacco products2, representing 26.7% of the 
population in that age range.  This marked a decrease in active tobacco use since 2002, 
when an estimated 30.4% of Americans in the same age range reported past-month 
tobacco use. Of these tobacco users, 57.5 million (approximately 82.7% of smokers) 
Americans over 12 years of age reported being active cigarette smokers, representing 
22.1% of that population. A similar decrease in active cigarette smoking was noted from 
2002, when 26.0% of Americans in the same age range reported past-month cigarette use  
(SAMHSA, 2013). 
This survey noted that while the ages of 18-25 showed the highest prevalence of 
active cigarette use with 31.8% of those adults actively smoking, this prevalence had 
declined from the 40.8% reported in 2002. A similar decline was also noted in the past-
month cigarette usage of 12-17 year olds. In 2002, 13.0% of Americans in that age range 
actively smoked, but in 2012, only 6.6% reported active cigarette use (SAMHSA, 2013). 
The 2012 NSDUH reported that over half of the active smokers surveyed (34.9 
million) reported smoking on a daily basis, accounting for 60.7% of active smokers. The 
report suggested that daily smoking increased with age, with 22.0% of active smokers 
aged 12-17 years old, 45.1% of active smokers aged 18-25, and 66.0% of active smokers 
over the age of 26 reporting daily use (SAMHSA, 2013). It was also noted that the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Active tobacco use is defined as past-month use or use within the previous 30 days. 
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proportion of active smokers who used cigarettes on a daily basis had decreased in all 
three age demographics since 2002. 
Less than half (41.9%) of these daily smokers reported smoking 16 or more 
cigarettes (approximately one pack or more) per day. 10.6% of 12-17 year old daily 
smokers, 25.1% of 18-25 year old daily smokers, and 45.1% of daily smokers over the 
age of 26 reported smoking at this level. The survey also reported a notable decline in 
approximately-one-pack-per-day smokers since 2002 (20.74% to 51.15% across age 
demographics) (SAMHSA, 2013). Data taken from the 2012 National Health Interview 
Survey (NHIS) conducted by the U.S. Census Bureau reported that the mean number of 
cigarettes smoked per day decreased from 16.7 in 2005 to 14.6 in 2012 (CDC, 2014a). 
Smoking-Attributable Mortality and the Cost of Tobacco Use 
 Smoking and cigarette smoke exposure has been linked to approximately 480,000 
premature deaths in the United States per year (USDHHS, 2014). Smoking contributes to 
over 5.1 million years of potential life lost annually (CDC, 2008) and a 107.6 billion 
dollars loss in productivity. The addition of smoking-related health care expenditures, 
estimated to be 171 billion dollars annually, equals an economic cost of approximately 
279 billion dollars each year due to smoking (USDHHS, 2014). 
 From data collected between 2005 and 2009, it was found that an average of 
278,540 men and 201,770 women over the age of 35 died annually from smoking-
attributable causes.  These averages include the estimated 41,280 deaths caused by 
environmental tobacco smoke exposure and the approximately 620 deaths caused by 
preventable smoking-related residential fires. In addition, it was found that smoking and 
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cigarette smoke exposure can lead to an average of 1,015 perinatal deaths annually, 
caused either by prenatal conditions causally related to smoking during pregnancy or 
Sudden Infant Death Syndrome (SIDS), which has been causally linked to both smoking 
during pregnancy and secondhand smoke in infancy (USDHHS, 2014). 
Lung cancer is the most common cause of smoking-attributable death, associated 
with 130,659 deaths annually. Smoking accounts for nearly 82.4% of all lung cancer 
mortality. COPD is the second most common with an estimated 100,600 smoking-related 
deaths annually, accounting for 78.8% of all COPD-related deaths. Coronary artery 
disease is the third most common cause of smoking-attributable mortality with 99,300 
annual deaths, accounting for nearly 24.1% of CAD-related deaths annually (USDHHS, 
2014). These and the nearly 150,000 remaining smoking-attributable deaths are presented 
in Table 2. 
Table 2: Annual death and smoking-attributable mortality (SAM) estimates for adults ≥ 35 
years of age. 
Disease Deaths SAM Attributable fraction 
Lung cancer 158,530 130,659 82.42% 
Other cancers 178,480 36,000 20.17% 
Coronary artery disease 412,590 99,300 24.07% 
Other heart disease 171,870 25,500 14.84% 
Cerebrovascular disease 134,920 15,300 11.34% 
Other vascular disease 29,990 11,500 38.35% 
Diabetes mellitus 70,810 9,000 12.71% 
Pneumonia/influenza/tuberculosis 55,590 12,500 22.49% 
COPD 127,740 100,600 78.76% 
Perinatal conditions 12,900 1,013 7.85% 
Residential fires - 620 - 
Secondhand smoke - 41,280 - 
TOTAL Attributable deaths   480,320   






 While the physiological effects of Nicotine on the cardiovascular system are 
potential causes of cardiovascular damage and dysfunction, it is generally thought that 
the greater threat posed by nicotine is in its addictive capacity. Exposure and addiction to 
nicotine through the use of tobacco products exposes smokers to the other dangerous 
health risks associated with smoking. 
 Nicotine, inhaled as a component of tobacco smoke, is driven into the airway 
where it rapidly absorbs into the pulmonary venous circulation. From the venous 
circulation, it enters the arterial circulation, where it will be granted access to the brain. In 
the brain, nicotine molecules bind to Nicotinic Cholinergic Receptors (nAChRs), 
acetylcholine-binding ligand-gated ion channels in the adrenal medulla and other 
locations in the brain and nervous system. Nicotine binding opens these channels, 
allowing sodium or calcium (Ca2+) to move into the neuron. The subsequent change in 
voltage activates further influx of Ca2+ via voltage-dependent calcium channels, leading 
to the release of neurotransmitters in the brain (Benowitz, 2010). 
 Nicotine lowers the threshold necessary to allow electric self-stimulation in the 
medial forebrain. This threshold reduction increases responsiveness to rewarding stimuli, 
leading to reinforcement of the drug’s effects. Nicotinic stimulation of cholinergic 
receptors (AChRs) also leads to the release of different neurotransmitters. Dopamine 
(DA) is released in the mesolimbic area, the corpus stratum, and the frontal cortex to 
induce feelings of pleasure, suppression of appetite, and facilitate the reinforcing effects 
of nicotine (Benowitz, 2010). 
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 Norepinephrine and acetylcholine both facilitate the sympathomimetic effects of 
nicotine, increasing the heart rate, blood pressure, contractility of the heart, and 
suppressing the appetite, leading to the states of stimulation associated with the use of 
tobacco products. Acetylcholine is also said to have an enhancing effect on cognitive 
ability. Glutamate release is thought to improve learning capability and leads to memory 
enhancement. Serotonin modulates the mood of the smoker and also contributes to 
appetite suppression. β-endorphins and γ-aminobutyric acid (GABA) released by the 
brain following activation of nAChRs lead to a reduction of anxiety and tension in the 
smoker, acting as a mood modulator and relaxant (Benowitz, 2008). 
	  
Figure 4: Neurotransmitters released by nicotinic stimulation of nAChRs and their effects 
on the body. (Modified from Benowitz, 2008.)  
 The overall active effects of nicotine are said to be feelings of pleasure and 
euphoria, decreased feelings of stress and anxiety, increased concentration, increased 
reaction time, and increased cognitive performance. The rapid absorption of nicotine into 
the circulation and its quick movement into the brain creates the “rush” associated with 
tobacco use. This “rush” and the feelings that come with it positively reinforce nicotine 
dependence and addiction to tobacco products. Other components of tobacco smoke, 
specifically products made from acetaldehyde, are also thought to aid this process by 
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acting as monoamine oxidase inhibitors. Monoamine oxidase would normally catalyze 
the metabolism of dopamine, norepinephrine, and serotonin. Inhibition of this enzyme 
prolongs the activity of the neurotransmitters, increasing the effect of the nicotine and 
potentially leading to increased addictiveness through conditioning (Benowitz, 2010). 
Decreased use or abstention from tobacco products can lead to cravings and 
withdrawal. These withdrawal symptoms include irritability, restlessness, depressed 
mood, decreased concentration, anxiety, increased appetite, insomnia, behavioral 
problems, and hedonic dysregulation, a state in which one is said to be unable to 
experience any pleasure or joy in life (Benowitz, 2008). 
Figure 5: The actions of nicotine on the brain’s reward pathway. Nicotine stimulates 
dopaminergic neurons in the Ventral Tegmental Area (VTA) directly, through their nAChRs, and 
indirectly, by stimulating glutamate inputs that innervate these neurons. This stimulation releases 
dopamine into the nucleus accumbens (NAc). Nicotine is also thought to activate endogenous 
opioid pathways, releasing opioid peptides into the NAc. (Modified from Nester et al., 2005)	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It is thought that the α4β2 nAChR is the principal mediator of nicotine 
dependence. The α4 and α6 subunits, specifically in the ventral tegmental area and the 
nucleus accumbens, are thought to have a critical role in mediating the reinforcement 
effects of the drug (Pons, S. et al., 2008). The effects of nicotine on this reward pathway 
are shown in Figure 5. Prolonged exposure to nicotine is said to increase the number of 
binding sites available in the brain in response to receptor desensitization in a process 
known as neuroadaptation. Daily smoking leads to a near-complete saturation of these 
receptors with nicotine, leading to complete desensitization of the α4β2 receptors. The 
desensitization of nAChRs leads to the states of cravings and withdrawal that are 
associated with nicotine dependence. 
  Smoking is often associated with the development of conditioning. For regular 
smokers, the taste and feel of a cigarette alone can begin the rewarding effects, even 
before the act of smoking itself starts. In fact, nicotine is thought to be able to change the 
brain’s plasticity, enabling conditioning to occur more easily and increasing behavioral 
responses to conditioned stimuli (Benowitz, 2010). Smokers often form an association of 
moods or specific circumstances with the rewarding effects of nicotine. These 
associations and the expected effects of nicotine can create the urge to use tobacco 
products, leading to the cravings and relapse-risk associated with tobacco cessation. 
 Negative conditioning can also occur with withdrawal-related stimuli, making it 
even harder for nicotine-dependent smokers to successfully quit. Much like nicotine can 
lower the electrical threshold needed to enable the reward response, withdrawal-related 
conditioning can elevate the brain’s reward threshold (Benowitz, 2010). This alteration 
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increases the magnitude of withdrawal symptoms and increases the difficulty of attaining 
successful cessation from tobacco products. 
Quit Interest and Quit Attempts 
 Despite the addictive properties of nicotine and the relatively high prevalence of 
smoking, most current smokers report being interested in quitting tobacco use. This has 
been attributed to a number of different factors. The increase in price of cigarettes and 
tobacco products has increased the financial burden of smoking. In the past decade, a 
number of smoke-free laws have been enacted, limiting where smokers can use tobacco 
products in public. These changes, coupled with high-impact anti-tobacco mass media 
campaigns and increased access to tobacco cessation aids and services, through insurance 
and publicly funded Quitlines, have lead to an increase in the interest in tobacco cessation 
(CDC, 2013b). 
In an analysis of the 2010 National Health Interview Survey, the quit interest and 
quit attempts of the smoking population were studied. The report found that 68.8% adult 
active smokers wanted to quit smoking (CDC, 2011). Quit interest was lowest among 
those older than 65 years old and seemed to be highest among those aged 25-44 years 
old.  The study also found that current smokers with private health insurance or a form of 
Medicaid were also more likely to report an interest in tobacco cessation than those with 
Medicare. 
They survey also found that 52.4% of smokers reported making a quit attempts 
for at least 1 day in the year preceding the interview (CDC, 2011). It was seen that the 
number of quit attempts decreased with increased age, with the ages of 18-24 more 
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actively attempting to initiate tobacco cessation. Following the trend seen in quit interest, 
those with private health insurance or Medicaid tended to more actively attempt to quit 
tobacco use, compared to those with Medicare or no health plan. 
Despite the high numbers associated with quit interest and quit attempts, few 
current smokers seem to be successful in successfully abstaining from tobacco use. Only 
6.2% of the population surveyed in the 2010 NHIS reported a recent cessation from 
tobacco products (CDC, 2011). It is not surprising that the rate of successful abstention 
from tobacco use is small, given the extent to which nicotine activates and alters the 
reward pathway and conditions the brain. Studies have shown that of those who 
successfully abstained from tobacco use for 30 days or less, only 12% remained abstinent 
at a follow-up interview 18 months later. Approximately 50% reported that they had 
relapsed and were actively smoking again on re-interview (Gilpin et al. 1997). 
More recent studies have studied the link between duration of abstinence and risk 
of relapse further. One study found that smokers who abstained for 1-7 days had a 78% 
risk of relapsing and those who abstained for 8-30 days had a 64% risk of relapsing. Once 
a former smoker had hit 1-6 months of abstinence, this risk dropped down to 42%, with 
58% remaining abstinent on reassessment. Approaching 6-12 months, only 22% relapsed 
and after 1-2 years, only 17% relapsed. Those who managed to abstain from smoking 
greater than 2 years only had a 5% risk of relapsing (Herd et al., 2009). 
Of those who attempted to or successfully quit the use of tobacco products, only 
approximately 31.7% reported the use of quit aids of some type, with more reporting the 
use of medications than counseling-based aids (CDC, 2011). This would imply that a 
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majority of smokers quitting unassisted, or without the use of tobacco cessation aids. A 
decreasing trend in unassisted quit attempts has been identified over the past 30 years, 
however. In 1983, 79.3% of smokers reported attempting to quit without the use of any 
quit aids. In 2006-2009, unassisted quit attempts had decreased to 50.3% among smokers 
(Edwards et al., 2014). This trend appears to correspond with the increasing availability 
and affordability of tobacco cessation aids.  
Aids for Tobacco Cessation 
 There are a number of Tobacco Cessation Aids available for those interested in 
quitting the use of tobacco products. There are pharmaceutical options, such as the over-
the-counter nicotine replacement products and prescription products, Bupropion and 
Varenicline and counseling options, such as hypnosis for tobacco cessation and publicly 
funded tobacco cessation Quitlines. There has also been a growing involuntary pressure 
on smokers to initiate tobacco cessation through public tobacco control polies at national, 
state, and local levels. This control has been focused in mainly four areas: the advertising 
of tobacco products, restrictions on the use of tobacco products in public places, 
increased taxation of tobacco products, and increased regulation of tobacco products and 
marketing. 
Tobacco Control Policy 
Following the release of 1964 Surgeon General report, the government was 
pressed to initiate the first national tobacco control policies. The first target of federal 
action was cigarette packaging. The Federal Trade Commission (FTC) attempted to 
mandate warning labels on cigarette packages effective as of 1965. Congress passed the 
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Cigarette Labeling and Advertising Act of 1965 in response, which required a warning3 
on cigarette packages. The Comprehensive Smoking Education Act of 1984 altered the 
requirement on warning labels required by the government by introducing four rotating 
health warnings to be put on all cigarette packages and advertisements.4  
Most recently, the enactment of the Family Smoking Prevention and Tobacco 
Control Act in 2009 attempted to modify these warnings further, introducing nine new 
graphic warning labels from the National Food and Drug Administration (FDA) that 
would comprise 50% of the cigarette carton and at least 20% of all advertisements. This 
change was challenged and delayed, however, and no further changes have been made. 
The first regulation of cigarette advertising did not come until 1969, through The 
Public Health Cigarette Smoking Act, which banned conventional ads for cigarettes on 
both radio and television, effective in 1971. The ban on cigarette advertising was 
extended to billboards and youth-directed media in 1999. Although movies were not 
covered by this extension, Hollywood responded by voluntarily removing smoking from 
most youth-rated films (USDHHS, 2014). 
The decrease of pro-cigarette marketing affected the reach of tobacco 
manufacturers, but it was the increase in antismoking marketing that prompted action 
from smokers. Although there have been a number of antismoking campaigns over the 
past 50 years, the Centers for Disease Control and Prevention (CDC) recently started 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 The required warning: "Caution: Cigarette Smoking May Be Hazardous to Your Health." 
4 “Smoking causes lung cancer, heart disease and may complicate pregnancy,” “Quitting smoking 
now greatly reduces serious risks to your health,” “Smoking by pregnant women may result in 




“Tips from former smokers,” the first federally funded nationwide paid media tobacco 
education campaign. In 2013, the CDC reported that approximately 200,000 Americans 
had quit smoking as a direct result of the 2012 campaign and estimated that 100,000 
would remain tobacco-free permanently. The CDC also estimated that 1.6 million quit 
attempts were initiated following the ad campaign (CDC, 2013a). 
The US Department of Defense was the first to place restrictions on tobacco use 
in public, discontinuing cigarettes from soldiers’ rations in 1975 and, by 1978, 
implementing smoke-free restrictions at certain instillations and designated smoking 
areas on other military bases. In 1993, the Joint Commission on the Accreditation of 
Health Care Organizations required hospitals to ban smoking indoors. Within a year, 96% 
of hospitals reported being smoke-free indoors, with nearly 40% of hospitals introducing 
further restrictions on where it was permissible to smoke on their campuses. The Pro-
Children Act of 1994 outlawed smoking in most public schools and all federally funded 
children’s services. As of last year, 36 states had adopted smoke-free legislation that 
prohibited smoking in most enclosed public places, such as workplaces, restaurants, and 
bars. Local governments enacted policies in the remaining states, with 3,500 
municipalities nationwide adopting smoking-free legislation (USDHHS, 2014). 
It has been shown that increasing the price of cigarettes through increased taxes 
on tobacco products has also yielded a decrease in tobacco consumption in adult smokers 
(Frieden et al., 2005). Tobacco is taxed on the federal, state, and local levels of 
government and these taxes have been increasing over the last decade. In 2000, the 
federal tax increased from $0.24 to $0.34 per pack. The federal tax on tobacco rose again 
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in 2002 to $0.39 per pack. In 2009, this tax jumped to $1.01 per pack through the 
Children’s Health Insurance Program Reauthorization Act. Over the same timeframe, 
state taxes on tobacco products have increased over 105 times. The mean state tax in 
2012 added $1.53 to each pack of cigarettes purchased, with the lowest state tax, $0.17, 
in Missouri and the highest, $4.35, in New York (USDHHS, 2014). 
The Family Smoking Prevention and Tobacco Control Act not only attempted to 
mandate increased warnings on cigarette products, but also created a regulatory 
framework within which the FDA could regulate the sale and production of tobacco 
products in a manner that was “appropriate for the protection of the public health” (FDA, 
2012). The Tobacco control Act gave the FDA the authority to standardize the allowable 
levels of compounds and ingredients in tobacco products and tobacco smoke that the 
agency had identified as harmful or potentially harmful to human health.  
The FDA was also given the authority to require the manufacturers of tobacco 
products to submit information on the health, toxicological, behavioral, or psychological 
effects of any products or their components, including smoke. Manufacturers were 
required to submit a premarket application to the FDA before marketing a new product or 
making a modification of an existing product, such as a change in ingredients or 
additives. In addition, they also need to obtain permits to produce risk-modified products, 
such as “Light” or “low-tar” variants, before they can introduce it into the market. As a 
part of this process, the manufacturers need to study and prove how the new product 
reduces the risk involved in the use of tobacco products (FDA, 2012). 
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Pharmaceutical Aids for Tobacco Cessation 
 The first pharmaceutical therapies for tobacco cessation came in the form of 
nicotine replacement therapies (NRTs). The first of these therapies was nicotine gum, 
such as Nicorette®, which was first approved by the FDA in 1984. Nicotine patches, 
such as Nicoderm®, were first approved in 1991 and the availability of these increased 
the number of aid-assisted quit attempts from less than 2 million per year to 
approximately 7 million per year. In 1996, the FDA approved nicotine gum and nicotine 
patches for over-the-counter (OTC) sale and this lead to another surge in 
pharmacologically assisted tobacco cessation attempts (Burton et al., 2000). Nicotine 
sprays and inhalers, such as Nicotrol®, were approved for use in 1997, but are not 
available as an OTC therapy for tobacco cessation. Lastly, nicotine lozenges, such as the 
Commit® Lozenge, were approved for use and approved for OTC sale in 2002. 
 The aims of these products are to offer the brain low levels of nicotine to maintain 
desensitization of the nAChRs, satiate cravings for tobacco products, and alleviate the 
withdrawal symptoms associated with abstinence of tobacco products. These medications 
are tapered with time to reduce dependence on nicotine and increase success in achieving 
tobacco cessation.  
NRTs offer the slow delivery of low levels nicotine into the body through 
different means of delivery. Nicotine patches offer slow absorption through the skin, 
while nicotine gums, lozenges, sprays, and inhalers offer quicker delivery through the 
oral and nasal mucosae (Cahill et al., 2013). The rapid absorption of nicotine in these 
products creates to the slight “rush” that users may feel, similar to the feelings of 
	  27 
euphoria and pleasure associated with cigarette smoking. Nicotine patches do not offer 
that same feeling due to the slowed absorption that occurs via epidermal delivery. 
 There are two common prescription pharmaceutical aids for tobacco cessation, 
Bupropion (also known as Zyban® and Wellbutrin®) and Varenicline (also known as 
Chantix®). Bupropion was first patented in 1969 as a novel, nontricyclic antidepressant 
and approved for use by the FDA to treat depression in 1985. Its use in tobacco cessation 
came in 1997, when a lower-dose, sustained release formula (Zyban®) was approved by 
the FDA for treatment of nicotine addiction. Bupropion is prescribed to patients seeking 
tobacco cessation as a 7-12 week treatment with an attempt at tobacco cessation first 
initiated ten days into the course of treatment. 
 Bupropion is thought to act as an antidepressant by inhibiting the dopamine 
transporter and the norepinephrine transporter and rapidly increase vesicular dopamine 
uptake. Contributing to its use as a tobacco cessation aid is the ability of bupropion and 
its metabolites (such as 2S,3S-hydroxybupropion) to act as nAChR antagonists (Dwoskin 
et al., 2006). Studies have also suggested that bupropion can reverse the nicotine-induced 
modifications in the threshold of the brain’s reward pathway, reducing the reinforcing 
effects of nicotine by increasing the decreased reward threshold associated with nicotinic 
stimulation (Epping-Jordan et al., 1998) and modulating the symptoms of withdrawal by 
decrease the nicotine-induced increase in the reward threshold associated with nicotinic 
withdrawal (Cryan et al., 2003). 
 Varenicline was first approved for use in the treatment of tobacco cessation in 
2006 as Chantix®. Varenicline acts as a partial-agonist of nAChRs, with a high affinity 
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and selectivity for binding to α4β2 receptors. This activity antagonizes nicotine, inhibiting 
its action at these receptors and blocking the increase in dopamine associated with 
tobacco use. In this way, treatment with Varenicline could decrease the reinforcing 
effects of nicotine and smoking, blocking the reward that has been associated with 
tobacco use, and increasing the accessibility of tobacco cessation (Garrison et al., 2009). 
 Varenicline is prescribed for a 12-week course of treatment with the first attempt 
at tobacco cessation initiated 7 days after the user begins taking the drug. The potential 
for an increased risk of cardiovascular adverse events in patients with cardiovascular 
disease was proposed (Singh et al., 2011), but further review concluded that there was no 
clear increase of risk associated with Varenicline users (Takagi et al., 2011). 
 In clinical studies comparing the use of NRTs to a placebo, it was found that the 
use of NRTs presented an odds ratio of 1.84 (95% confidence interval (CI) = 1.71 - 1.99), 
indicating that use of NRTs were associated with higher odds of successful tobacco 
cessation compared to the use of a placebo product. In comparing the different types of 
NRTs, it was found that they all yielded similar outcomes in aiding tobacco cessation. In 
studies that compared the use of Bupropion to a placebo, Bupropion was found to be 
more effective in aiding tobacco cessation than the placebo, yielding an odds ratio of 1.82 
(95% CI = 1.60 - 2.06). In studies that compared the use of Varenicline to a placebo, 
Varenicline proved more effective than the placebo, producing an odds ratio of 2.88 
(95% CI = 2.40 - 3.47) (Cahill et al., 2013). 
 These studies indicated that all three pharmaceutical aids for tobacco cessation, 
NRTs, Bupropion, and Varenicline, increased the chances of achieving tobacco cessation 
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compared to placebo. Compared against each other, NRT products and bupropion yielded 
similar results, making them equally as effective in aiding tobacco cessation. Varenicline 
was found to be more effective than either NRT products or Bupropion and as effective 
as a combination treatment of nicotine replacement products yielding an odds ratio of 
1.06 (95% CI of 0.75 - 1.48) (Cahill et al., 2013). These results and other comparisons 
have been summarized in Table 3. 
Table 3: Comparison of pharmaceutical therapies to placebo controls and to each other 
 Tobacco Cessation Aid vs. Placebo Odds Ratio 95% CI 
NRT vs. placebo 1.84 1.71 - 1.99 
NRT patch vs. placebo 1.91 1.71 - 2.14 
NRT gum vs. placebo 1.68 1.51 - 1.88 
Other NRT vs. placebo 2.04 1.75 - 2.38 
Combination NRT vs. placebo 2.73 2.07 - 3.65 
Bupropion vs. placebo 1.85 1.63 - 2.1 
Varenicline vs. placebo 2.89 2.4 - 3.48 
Bupropion vs. NRT 0.99 0.86 - 1.13 
Bupropion vs. NRT patch 0.97 0.83 - 1.13 
Bupropion vs. NRT gum 1.1 0.93 - 1.3 
Bupropion vs. NRT combination 0.68 0.5 - 0.91 
Varenicline vs. NRT 1.57 1.29 - 1.91 
Varenicline vs. NRT patch 1.51 1.22 - 1.87 
Varenicline vs. NRT gum 1.72 1.38 - 2.13 
Varenicline vs. NRT combination 1.06 0.75 - 1.48 
Varenicline vs. Bupropion 1.56 1.26 - 1.93 
Source: Created from results presented in Cahill et al., 2013 
Counseling-based Interventions for Tobacco Cessation 
  Smokers looking for non-pharmaceutical interventions to aid their attempts to 
abstain from tobacco use have options in the form of tobacco cessation counseling. This 
counseling can come in the form of group or telephone-based sessions, more in-depth 
individual and behavioral-based therapies, or even the issuing and use of self-help 
materials.  
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 In the use of hypnotherapy-based tobacco cessation services, hypnosis is used in 
combination with cognitive behavioral therapy to alter the smoker’s patterns of behaviors 
by strengthening the user’s will against smoking and to increase their ability to 
concentrate on a given quit plan and weaken the desire to smoke. A commonly used 
method, outlined by Dr. Herbert Spiegel, attempts to do this by focusing on three points 
in a single session. In Spiegel’s method, the trained hypnotherapist attempts to change the 
tobacco user’s perceptions of smoking by inducing a deep concentration through 
hypnotherapy and instructing the smoker that, “Smoking is poison,” “The body is entitled 
to protection from smoke,” and that “There are advantages to life as a nonsmoker.” 
During this session, the patient will also be trained in self-hypnosis, which can be used by 
the patient in the future to strengthen their resolve against smoking when they feel they 
need it (Barnes et al., 2010). 
 There is little consensus about hypnotherapy actually induces its effects, and it’s 
held that the success of this method is influenced by other factors, such as hypnotisability 
and any transference that might exist between the patient and the therapist (Barnes et al., 
2010). Some have said that hypnotherapy enhances the subject’s responsiveness to 
suggestions and that this could alter the unconscious impulses that maintain smoking. It 
has also been thought that placebo and expectation factors may play into the success of 
hypnotherapy. Another theory suggests that the patient’s motivation to quit smoking is 
reinforced through the self-hypnosis techniques learned by the patient, which, when 
practiced and applied, can act as a coping mechanism to maintain the desired change in 
behavior (Carmody et al., 2008). 
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 In a study that compared hypnotherapy with a waiting-list control (no treatment), 
those who received hypnotherapy had a higher point-prevalence rate for tobacco 
cessation after 12 months. A review of studies that compared hypnotherapy to control 
groups that received only brief attention or advice showed some benefits for the hypnosis 
group, but the analysis also produced wide confidence intervals. When compared to 
control groups that received psychological treatments only, no appreciable difference was 
noted between the two groups (Barnes et al., 2010). 
A more recent study compared hypnotherapy in combination with nicotine patch 
use and behavioral counseling in combination with nicotine patch use.  The study noted 
that those in the behavioral group reported more severe nicotine withdrawal symptoms 
after two weeks of nicotine abstention, but reported no difference in withdrawal 
symptoms after the third week. At a 12-month follow up, the group that had received 
hypnotherapy had a higher rate of tobacco cessation (20% confirmed biochemically or by 
proxy) compared to the group that received behavioral therapy (14% confirmed 
biochemically or by proxy) (Carmody et al., 2008). 
 While the review of the literature showed some instances where hypnotherapy 
yielded better results than no therapy or other types of counseling, these were usually 
noted in a small studies or associated with wide confidence intervals, making these 
findings less significant. The Cochrane Review concluded that there was no clear 
evidence of a greater long-term benefit compared to other interventions or no intervention 
was found (Barnes et al., 2010). 
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 The first tobacco cessation quitlines started in the early 1980s as a component of 
the Cancer Information Service, provided by the US National Cancer Institute. The initial 
program was limited and the service could only be initiated by a call from the tobacco 
user, but the program ultimately demonstrated some level of interest in phone-based 
tobacco cessation services. In 1992, California was the first to provide a publicly funded 
statewide quitline. This quitline was a little more robust, including proactive calls to 
tobacco users after they made the initial call. All 50 states now have a quitline accessible 
through a single phone number, 1-800-QUIT-NOW (Lichtenstein et al., 2010). 
 The initial call typically lasts 30-40 minutes and it covers assessment, enhancing 
motivations to quit smoking, increasing self-confidence in executing a successful quit 
plan, developing coping strategies to deal with withdrawal, and adopting a nonsmoker 
self-image. At the end of the call, the tobacco cessation counselor and the caller set a 
specific quit date. Subsequent calls are made around that date, with calls coming on that 
date, 3 days after the set quit date, 1 week after, 2 weeks after, then 1 month after. These 
calls manage withdrawal symptoms, review and revise coping strategies, examine 
instances of relapse (“slipping”), and revisit the user’s self-efficacy and motivation to 
successfully quit tobacco use.  
 The USDHH showed this model of multiple proactive calls to be more effective 
than a single brief call or self-help materials only through 9 trials that yielded an odds 
ratio of 1.6 with 95% confidence intervals of 1.5 to 1.8. This showed that the quitlines 
were about as effective as certain NRTs, such as nicotine gum (Lichtenstein et al., 2010). 
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 Over the past 10-15 years, efforts have been made to increase the reach and 
effectiveness of the quitlines, including proactive recruitment calls made to smokers 
based off of healthcare provider referrals and the inclusion of free or discounted NRTs or 
other pharmaceutical therapies as a part of its services. The Minnesota quitline studied 
the effect of offering an 8-week supply of NRTs at no cost on its reach and outcome in 
2002. This change was not covered by any paid media announcements and there were no 
changes in their media efforts to encourage cessation at that time, though major news 
outlets and newspapers covered the addition of NRTs at the time (An et al., 2006). 
 Prior to the introduction of NRTs into their program (Pre-NRT), the quitline 
reported approximately 155 callers registering for their services each month. After NRTs 
were included, that number had jumped to approximately 679 callers per month, of which 
68% were mailed NRTs (mostly NRT patches). Pre-NRT, the program reported a 17.6% 
tobacco cessation rate at 30 days after initiation. This rose to 31.1% at the 30-day interval 
after offering NRTs to their callers (An et al., 2006). After adjusting for a change in caller 
characteristics, such as an increased report in readiness to quit following the inclusion of 
the NRTs into the program, the post-NRT quitline reported an odds ratio of 1.75 with a 
95% confidence interval of 1.09 – 2.83, indicating an increased chance of successful 
tobacco cessation with this new model (An et al., 2006). 
 The success of this trial has lead to 87% of North American Quitline Consortium 
(NAQC) quitlines providing free tobacco cessation medications to its callers in 2012. The 
consortium announced that it had received over 1.3 million calls to the US quitline in 
2012, translating to nearly 500,000 unique tobacco users calling and reaching over 1% of 
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adult smokers in the US. The NAQC calculated an overall quit rate of 28.5% among 
those that used its services that year (Saul et al. 2013). These numbers show that while 
the program can effectively help smokers initiate and maintain tobacco cessation, its 
reach is still limited, and that further growth is needed to impact smoking rates in the US. 
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SPECIFIC AIMS AND OBJECTIVES 
Despite the evidence linking active tobacco use and the development of serious and fatal 
health risks, the smoking of cigarettes is still significantly prevalent in the adult 
population of the United States, with the 2012 National Health Interview Survey 
reporting that 18.1% of adults (42.1 million people 18 years of age or older) were current 
tobacco users. (CDC, 2014a) Due in part to changes in national and local tobacco control 
policies, the increasing cost associated with smoking, and a recognition of the health 
consequences associated with smoking, a growing interest in initiating tobacco cessation 
has been noted in active tobacco users. (CDC, 2011) Tobacco cessation aid use was noted 
to be low among those who initiated or attempted to initiate tobacco cessation (CDC, 
2011), but a review of the literature has indicated that the number of unassisted quit 
attempts has been decreasing with increasing availability of these quit aids. (Edwards et 
al., 2014) Therefore, this study plans to look at the following objectives: 
1. To determine the quit interest of active tobacco users and analyze for associations 
between interest and other smoking-related variables. 
2. To quantify the number of quit attempts initiated by active and former tobacco 
users and analyze these for potential associations to other smoking-related 
variables. 
3. To analyze and determine the prevalence of tobacco cessation aid use in a 
representative population of active and former tobacco users. 
4. To determine the perceived effectiveness of certain tobacco cessation aids and to 
compare this with values of efficacy obtained in clinical trials of these products. 
	  36 
METHODS 
Procedures and Participants 
This study was conducted as a part of a large, prospective, observational and 
interventional study conducted in 2012 by the National Research Associates Program 
(NARAP). In this study, trained research staff, premedical college students known as 
Research Associates (RAs), recruited subjects from ten Emergency Departments (EDs) in 
eight different states. The parent study was primarily interested in studying tobacco use 
among ED patients and visitors and facilitating public health interventions, such as 
initiating referrals to tobacco cessation quitlines, within this population in the Emergency 
Department. The adjunct study we conducted focused on using the obtained tobacco use 
statistics to analyze quit interest, quit attempts, and tobacco cessation aid use among 
active and former smokers.  
Trained research staff screened ED patients for tobacco use over a period of 14 
months. Eligible participants were 18 years of age or older and were able to give 
informed consent to be enrolled in the study. All candidates were assured that they would 
receive treatment as usual by the hospitals’ medical staff regardless of participation. 
Potential candidates were excluded if they had illnesses that precluded conversation, such 
as those that required more immediate attention of the hospital staff (persistent vomiting, 
acute events) or that rendered the patient unable to respond to the approaching RA. Those 
that lacked adequate comprehension of the study requirements were also excluded. This 
included patients with altered mental statuses, patients with acute intoxication, those 
exhibiting hostile or aggressive behavior, or those who possessed an insurmountable 
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language barrier. Sites participating in the study kept a record of subjects approached, 
including those excluded, and subjects enrolled in the study, shown in Figure 7. 
 
Figure 6: Exclusion criteria considered before enrolling a subject. Potential study participants 
were excluded if they were deemed too ill to complete the survey, had an altered mental status, 
were intoxicated, or were exhibiting hostile behavior, had an insurmountable language barrier, 
were under the age of 18, or were unable to give informed consent to be apart of the study. 
 After determining the candidate’s eligibility and obtaining informed consent, the 
RAs used a scripted interview prompt to obtain demographical information and a detailed 
history of tobacco use from the participant. The tobacco history obtained provided data 
on smoking-related variables, such as the current tobacco use status, what tobacco 
products were used, if any, when the participant had last used tobacco products, how 
many tobacco products they typically used on a daily basis, if at all, how many times they 
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had attempted to quit smoking during the duration of their use of tobacco, which, if any, 
quit aids they might have used in those cessation attempts and, if so, how helpful the 
subject felt they were on a scale of 0 – 10, with 0 indicating that they were “not at all 
helpful” and 10 indicating that they were “very helpful.” They were also asked if they 
had health insurance and, if so, were asked to identify a type: private health insurance, 
Medicare, or Medicaid. 
Participants were asked about their intention to initiate tobacco cessation in the 
future on a scale of 1 – 10, with 1 indicating that it was “not at all important” and 10 
indicating that it was “the most important goal of [their] life.” They were then asked to 
rank their perceived readiness to quit smoking on a scale of 1 – 10, with 0 indicating that 
they were “not at all ready” and 10 indicating that they were “100% ready.”  
 Participants that indicated that they had used tobacco produces for greater than 30 
days at any time in their lives were offered a referral to that state’s quitline. Those that 
indicated having ever smoked were also given educational pamphlets on smoking 
cessation published by the US Department of Health and Human Services and offered a 
list of tobacco-cessation treatment options, including the National Quitline number.  
Data Collection and Analysis 
Answers were collected using Vanderbilt University’s Research Electronic Data 
Capture (REDCap™) service. Using this online software, RAs recorded the participant’s 
answers by either selecting their answer from a series of multiple choices or typing in the 
required information into a text box. The responses recorded by the parent study were 
exported from REDCap™ into IBM’s Statistical Product and Service Solutions (SPSS) 
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software. SPSS was then used to aggregate these responses and analyze the data for 
trends, using Cramer’s V and Chi-square tests to measure the level of association and 
statistical significance of the relationships between variables. This analysis was 
conducted based on the stated aims and objectives of our study and was conducted using 




Figure 7: Results from parent study and data selection for present study. Of the 19,149 study 
participants enrolled in the parent study, the 10,303 that indicated that they had ever smoked for 





Throughout the course of the study, 10,303 study participants indicated that they had 
used cigarettes for longer than a month at some point in their lives, shown in Table 4. Of 
these subjects, 5,200 participants (50.5%) reported current tobacco use, having smoked 
within the 7 days preceding the survey and 4,818 participants (46.8%) reported former 
cigarette use, describing their current cigarette usage as “not at all.” The remaining 285 
participants (2.7%) did not specify their current tobacco use status. Participants reported 
smoking for an average of 20.55 ± 14.82 years. Smokers who used cigarettes for longer 
than a month reported smoking an average of 14.8 ± 12.2 cigarettes per day 
(approximately three-quarters of a pack per day). Those who reported actively smoking at 
the time of the interview only reported smoking an average of 12.0 ± 9.3 cigarettes per 
day, however. 
Table 4: Current Tobacco Use Frequency and Length Among Ever Smokers (n=10303) 
Current Tobacco Use Frequency Responders Years Smoking 
Every Day 3860 (37.5%) 24.28 ± 14.09 
Some Days 1340 (13.0%) 18.75 ± 14.99 
Not at all 4818 (46.8%) 18.30 ± 14.72 
Unknown 285 (2.7%) 
 Total 10303 20.55 ± 14.82 
Of the 5,200 study participants that reported actively using cigarettes, 5,018 
indicated their perceived readiness to initiate tobacco cessation on a scale from 1 to 10. 
The mean response of these participants was 6.01 ± 3.44, with 940 active smokers 
(18.7%) indicating that they were “not at all ready” to quit smoking with a response of a 
1 and 1,543 active smokers (30.8%) indicating that they were “100% ready” to quit 
smoking with the response of a 10. A majority of current tobacco users seemed to exhibit 
	  41 
interest in initiating tobacco cessation, with 55.2% reporting quit readiness as being 6 or 
greater (6 – 10). In comparison, 44.8% of current tobacco users reported their readiness 
as being a 5 or less (1 – 5). The distribution of these responses is shown in Table 5. 
Table 5: Self-reported readiness and intent to quit among current smokers 
Readiness to Quit Responses 
 
Intent to Quit Responses 
1 (not at all ready) 940 (18.7%) 
 
1 (no intent) 1098 (22.0%) 
2 256 (5.1%) 
 
2 269 (5.4%) 
3 225 (4.5%) 
 
3 237 (4.7%) 
4 191 (3.8%) 
 
4 188 (3.8%) 
5 636 (12.7%) 
 
5 612 (12.4%) 
6 227 (4.5%) 
 
6 238  (4.8%) 
7 321 (6.4%) 
 
7 370 (7.4%) 
8 418 (8.3%) 
 
8 447 (8.9%) 
9 261 (5.2%) 
 
9 229 (4.6%) 
10 (100% ready) 1543  (30.8%) 
 





Of the 5,200 study participants that reported actively using cigarettes, 5,001 
indicated their intent to initiate tobacco cessation on a scale from 1 to 10. The mean 
response of these participants was 5.66 ± 3.45, with 1,098 active smokers (22.0%) 
indicating that quitting was not important to them with a response of a 1 and 1,313 active 
smokers (26.3%) indicating that quitting was an important goal for them with the 
response of a 10.  Just under half of respondents indicated intent to quit smoking, with 
51.9% reporting an intent of greater than 6 (6–10), compared to the 48.1% of current 
tobacco users who reported an intent of 5 or less (1–5). The distribution of these 
responses is also shown in Table 5. 
In comparing these two variables against each other, the strength of association 
was found by calculating the Cramer’s V coefficient, V=0.415, with an approximate 
significance (p) < 0.05. This signified a strong, significant association. This was 
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confirmed by finding the Pearson correlation, r=0.774, p < .001, indicating a strong 
positive relationship between the two variables. It was, however, noted that the number of 
those who felt ready to initiate tobacco cessation (55.2%) was greater than those who 
expressed intent to initiate tobacco cessation (51.9%). Similarly, the number of those who 
reported zero intention to quit (22.0%) was greater than those who reported that they 
didn’t feel ready to quit (18.7%). This discrepancy suggested to us that while many 
expressed a desire to quit smoking, fewer felt that they could or would actually follow 
through on that interest and translate it into initiation of tobacco cessation. 
Table 6: Readiness and Intent to initiate tobacco cessation as reported by active smokers 	   Current Tobacco Usage 	   	   Current Tobacco Usage Readiness Every Day Some Days 
	  
Intent Every Day Some Days 
1 774 151 
	  
1 909 171 
2 205 49 
	  
2 206 62 
3 165 58 
	  
3 187 50 
4 155 35 
	  
4 142 45 
5 509 124 
	  
5 471 134 
6 189 36 
	  
6 186 48 
7 243 69 
	  
7 273 87 
8 313 94 
	  
8 328 105 
9 169 83 
	  
9 145 75 
10 925 454 
	  
10 786 371 
Total 3647 1153 
	  
Total 3633 1148 
        Cramer’s V: 0.153, p < .001                  Cramer’s V: 0.146, p < .001 
 Comparing readiness to initiate tobacco cessation with current tobacco usage 
among active smokers, shown in Table 6, we found a weak, but significant association 
between the two variables (V=0.153, p < 0.01). In comparing responses, we found that 
daily smokers were less likely to report that they were ready to initiate tobacco cessation 
(50.4%) compared to occasional smokers (63.8%). Daily smokers were also more likely 
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to indicate that they were not ready to initiate tobacco cessation, with 49.6% providing a 
response of a 5 or less (1-5), compared to occasional smokers (36.2%). 
In looking at intent to initiate tobacco cessation as a function of current tobacco 
usage among active smokers, also shown in Table 6, we again found a weak, but 
significant association between the two variables (V=0.146, p < 0.01). Following the 
trend found in quit readiness, we found that daily smokers were less likely to report that 
they intended to initiate tobacco cessation (47.3%) compared to occasional smokers 
(59.8%). Daily smokers were also more likely to indicate that they did not intend initiate 
tobacco cessation (52.7%) compared to occasional smokers (40.2%). 
Our study looked at quit interest among active smokers and compared these 
responses by the average number of cigarettes smoked per day, as well. Though these 
variables were only weakly associated (V=0.113-0.165), they were statistically 
significant (p < 0.05), and we could see a trend observationally. Shown in Table 7, quit 
interest (both readiness to quit and intent to quit) appeared to decline with an increase in 
amount smoked, highest among active smokers who only smoked 1 to 5 cigarettes a day 
and lowest in those who smoked over a pack per day.  
Table 7: Quit interest among active smokers by amount smoked per day 
 
Average Number of Cigarettes Smoked Per Day 
Quit Interest 1 to 5 6 to 10 11 to 15 16 to 20 21 to 30 
Ready to Quit 64.7% 58.5% 57.2% 55.1% 45.4% 
Intend to Quit 60.6% 55.6% 54.2% 51.2% 44.2% 
  
Looking at the distribution of quit interest categorized by age, as in Table 8, it 
was found that those aged 41-64 reported the highest readiness and intent to quit. It was 
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also noted that the ages of 18-25 provided the lowest intent to quit and that those over 65 
years of age were the least ready to quit smoking. 
Table 8: Comparison of quit interest reported by different age groups 
 
Study Participant Age 
Quit Interest 18 - 25 26 - 40 41 - 64 65+ 
Ready to Quit 47.7% 51.9% 57.8% 47.4% 
Intend to Quit 43.7% 48.2% 54.3% 48.1% 
An analysis of readiness to quit and intent to quit as a function of health insurance 
(private insurance, Medicaid, Medicare, or no health insurance), shown in Table 9, 
yielded weak, but significant associations (V=0.101-0.151, p < 0.05). Quit interest among 
study participants with private health insurance appeared to be lower than quit interest 
among participants with Medicaid, Medicare, or without health insurance in both 
measures, readiness to quit smoking and intent to initiate tobacco cessation. 
Table 9: Quit interest among active smokers with and without health insurance 
 
Health Insurance Possessed 
Quit Interest Private Medicaid Medicare None 
Ready to Quit 52.2% 56.4% 58.2% 52.7% 
Intend to Quit 48.1% 55.6% 56.1% 48.5% 
 
Table 10: Number of quit attempts reported by current and former smokers 
 
Current Tobacco Usage 
 Number of Quit Attempts Every Day Some Days Not at all Total 
None longer than 24 hours 752 290 173 1215 (12.3%) 
1 - 5 times 2223 646 3665 6534 (66.2%) 
6 - 10 times 395 137 395 928 (9.4%) 
11 -20 times 168 60 153 381 (3.9%) 
More than 20 times 190 88 199 477 (4.8%) 
Could not provide an answer 53 78 206 337 (3.4%) 
Total 3781 1299 4791 9871 
Of those surveyed, 9,871 study participants responded to questions about the 
number of quit attempts they had initiated during the course of their current or former 
cigarette use, shown in Table 10. A majority (66.2%) of smokers reported attempted to 
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initiate tobacco cessation 1–5 times, with 76.5% of former smokers reported quitting 
within that many attempts. While a majority of daily smokers (58.8%) and occasional 
smokers (49.7%) reported attempting to at least quit 1–5 times, a relatively high number 
of these smokers (19.9% and 22.3%, respectively) reported never successfully initiating 
tobacco abstinence for longer than 24 hours. 
Table 11: Quit attempts among active and ever smokers compared by age 
	   Ever Smokers, by age Quit Attempts 18 - 25 26 - 40 41 - 64 65+ 
Never quit > 24 hr. 233 (22.4%) 335 (14.9%) 541 (12.2%) 96 (12.9%) 
1 - 5 times 675 (65.0%) 1500 (66.8%) 3016 (67.8%) 1208 (68.5%) 
6 - 10 times 73 (7.0%) 205 (9.1%) 481 (10.8%) 147 (9.2%) 
11 - 20 times 27 (2.6%) 86 (3.8%) 181 (4.1%) 74 (4.6%) 
More than 20 times 30 (2.9%) 120 (5.3%) 74 (5.2%) 81 (5.0%) 
Chi-square: 251.91, degrees of freedom (df) = 12, approximate significance: p < .001 	   Current Smokers, by age Quit Attempts 18 - 25 26 - 40 41 - 64 65+ 
Never quit > 24 hr. 221 (28.4%) 301 (19.5%) 466 (20.2%) 46 (17.8%) 
1 - 5 times 452 (58.2%) 921 (59.6%) 1325 (57.4%) 143 (55.4%) 
6 - 10 times 56 (7.2%) 159 (10.3%) 272 (11.8%) 35 (13.6%) 
11 - 20 times 23 (3.0%) 69 (4.5%) 115 (5.0%) 16 (6.2%) 
More than 20 times 25 (3.2%) 95 (6.1%) 132 (5.7%) 18 (7.0%) 
Chi-square: 55.23, df= 12, approximate significance: p < .001 
Looking at self-reported quit attempts among different age demographics, shown 
in Table 11, we found that active smokers over 65 years of age were most likely to have 
attempted to quit smoking once or more (82.2%), followed by 26-40 years of age 
(80.5%), 41-64 (79.8%), and the 18-25 age range (71.6%). Factoring in former smokers, 
the 41-64 age range had the largest proportion of those who attempted to quit more than 
once (87.8%), followed by those over the age of 65 (87.1%), 26-40 (85.1%), and with the 
lowest once again found in the 18-25 age range (76.6%).  
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Table 12: Quit attempts among active smokers with and without health insurance  
 
Health Insurance Possessed 
Number of Quit Attempts Private Medicaid Medicare None 
Never quit > 24 hr. 328 (19.8%) 274 (20.5%) 199 (18.8%) 306 (39.4%) 
1 - 5 times 942 (56.8%) 791 (59.3%) 593 (56.1%) 271 (34.9%) 
6 - 10 times 192 (11.6%) 136 (10.2%) 130 (12.3%) 75 (9.7%) 
11 - 20 times 93 (5.6%) 54 (4.0%) 56 (5.3%) 55 (7.1%) 
More than 20 times 102 (6.2%) 79 (5.9%) 79 (7.5%) 69 (8.9%) 
Chi-square: 183.61, df = 12, approximate significance: p < .001 
In analyzing self-reported quit attempts in relation to healthcare coverage, shown 
in Table 12, it was found that active smokers with health insurance were most actively 
attempting to initiate tobacco cessation, with 81.2% of smokers with Medicare, 80.2% of 
smokers with private health insurance, and 79.5% of smokers with Medicaid reporting 
more than one quit attempt. In comparison, only 60.6% of smokers without any form of 
health insurance reported attempting tobacco cessation more than once. 
Table 13: Tobacco cessation aid use among ever smokers 
Tobacco Cessation Aids Used? Reported Use 
  Yes (Any quit aid used) 3086 (30.7%) 
  No (Unassisted/"cold turkey") 6954 (69.3%) 
Total 10040 
 Of the 10,040 valid responses to our study, 6,954 (69.3%) indicated that they 
never used tobacco cessation aids, attempting to quit unassisted or “cold turkey.” The 
remaining 30.7% reported using some form of tobacco cessation aid (Table 13). In 
looking specifically at quit aid use among daily, occasional, and former tobacco users, 
shown in Table 14, it was found that 42.1% of daily, 29.8% of occasional, and 21.7% of 
former smokers reported using quit aids in previous quit attempts. 
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Table 14: Tobacco cessation aid use among active and former smokers 
 
Current Tobacco Usage 
 Quit Aids Used? Every Day Some Days Not at all Unknown Total 
Yes 1626 (42.1%) 399 (29.8%) 1046 (21.7%) 15 3086 
No 2234 (57.9%) 941 (70.2%) 3772 (78.3%) 7 6954 
Total 3860 1340 4818 22 10040 
Cramer's V: 0.206, Approximate significance: p < .001 
  In comparing tobacco cessation aid use to number of quit attempts initiated 
(Table 15), we found a weak-to-moderate association between these two variables, 
indicated by a V of 0.196 and a p of less than 0.05. Quit aids use was more commonly 
reported by current and former smokers who had previously attempted tobacco cessation 
greater than 5 times. Current and former smokers that had attempted to initiate tobacco 
cessation less than 5 times or who had never successfully quit for longer than 24 hours 
were more likely to have initiated unassisted quit attempts or no quit aid usage at all. 
Table 15: Tobacco cessation aid compared to quit attempts among ever smokers 
 
Quit Attempts (current and former smokers) 
 Quit Aids 
Used? None > 24h. 1 - 5 5 - 10 11 - 20 Over 20 
Yes 203 (7.2%) 1802 (63.5%) 426 (15.0%) 197 (6.9%) 211 (7.4%) 
No 1012 (15.1%) 4732 (70.7%) 501 (7.5%) 184 (2.7%) 266 (4.0%) 
Cramer's V: 0.196, Approximate significance: p < .001 
Quit attempts were most commonly aided by some form of nicotine replacement 
therapy, such as nicotine patch, gum, lozenges, and sprays (68.9% of those who reported 
using any form of quit aid), followed by prescription tobacco cessation medications, such 
as Bupropion and Varenicline (21.1%). Pharmacological interventions were more 
commonly used to aid smoking cessation than counseling-based interventions, with only 
431 participants (12.9% of quit aid users) reportedly using advice obtained from a health 
professional, 265 (7.9%) undergoing hypnotherapy, 206 (6.2%) consulting self-help 
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materials, 166 (5%) participating in cessation groups, and 133 (4.0%) using state tobacco 
cessation quitlines. The distribution of cessation aid use is shown in Table 16.  
Table 16: Tobacco cessation aids used among smokers who reported aided quit attempts 
Tobacco Cessation Aids Reported Use 
  Nicotine Replacements 2306 (68.9%) 
  Pills (Bupropion, Varenicline) 707 (21.1%) 
  Cessation Groups 166 (5.0%) 
  Hypnosis 265 (7.9%) 
  Advice from a Health Professional 431 (12.9%) 
  Self-Help Materials 206 (6.2%) 
  Tobacco Cessation Quitlines 133 (4.0%) 
  Other 318 (9.5%) 
Total Users 3348 
Nicotine replacement products were the most common quit aid used, with 22.4% 
of all participants indicated that they had tried one in previous quit attempts. As seen in 
Table 17, the nicotine patch was the single most common tobacco cessation aid used by 
study participants, with 1,754 (17.0%) of all study participants (52.4% of cessation aid 
users) reportedly having used it in the past. Nicotine gum was the second most common 
form of nicotine replacement, followed by lozenges. 
Table 17: Nicotine replacement therapies used by smokers 
Nicotine Replacement Therapy Used Reported Use 
Nicotine Patch 1754 (17.0%) 
Nicotine Gum 979 (9.5%) 
Nicotine Lozenges 190 (1.8%) 
Other NRTs 88 (0.9%) 
Total 2306 (22.4%) 
Of the 979 study participants that reported using nicotine replacement gum in 
previous quit attempts, 951 gave an assessment of its effect in helping them abstain from 
smoking using a scale of 0 (not helpful at all) to 10 (very helpful), shown in Table 18. 
The mean response for the effect of nicotine gum was 3.69 ± 3.39, with a majority 
(57.8%), reporting that it was not helpful in aiding their tobacco cessation attempts, 
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giving it a score of 4 or less. Only 30.1% reported that they felt it aided their quit 
attempts, giving it a score of 6 or more. The remaining 12.1% gave it the median, 5, 
indicating that they were unsure of its effect on their attempted abstinence from smoking. 
Table 18: Perceived effectiveness of nicotine replacement gum/lozenges in aiding cessation 
Effect of NRT Gum Responses 
 
Effect of NRT Lozenge Responses 
0 (not at all helpful) 291 (30.6%) 
 
0 (not at all helpful) 56 (30.1%) 
1 53 (5.6%) 
 
1 9 (4.8%) 
2 94 (9.9%) 
 
2 11 (5.9%) 
3 63 (6.6%) 
 
3 8 (4.3%) 
4 49 (5.2%) 
 
4 8 (4.3%) 
5 115 (12.1%) 
 
5 22 (11.8%) 
6 47 (4.9%) 
 
6 14 (7.5%) 
7 74 (7.8%) 
 
7 7 (3.7%) 
8 58 (6.1%) 
 
8 20 (10.8%) 
9 30 (3.2%) 
 
9 8 (4.3%) 
10 (very helpful) 77 (8.1%) 
 




 Of the 190 participants that reported trying nicotine replacement lozenges in 
previous quit attempts, 186 provided an assessment of its effect in helping them quit 
smoking using that same 0 – 10 scale, also shown in Table 18. The mean response for the 
effect of the lozenges was 4.26 ± 3.67, with the majority of responses (49.5%) indicating 
that they were not helpful during the course of their quit attempt. Meanwhile, 38.7% of 
those surveyed thought that the lozenges were effective in aiding their quit attempts. The 
remaining 11.8% gave lozenges the median score of 5, indicating uncertainty on their 





The 2010 National Health Interview Survey found that 68.8% of adult active 
smokers were interested in initiating tobacco cessation, with the lowest interest found 
among those over 65 years of age (53.8%) and the highest among those aged 25-44 years 
of age (72.5%), followed closely by those aged 45-64 years of age (69.0%). (CDC, 2011) 
Our study found that 53.7% of adult active smokers reported being ready to quit smoking 
with a response of greater than 6 and 50.3% reported intent to quit smoking (Table 6). 
Moreover, our study found that quit interest was highest in those aged 41-64 years 
of age, followed by those aged 26-40 years of age, shown in Table 8. Our ages were 
categorized differently than found in the NHIS, with our study using 26-40 and 41-64 
instead of 26-44 and 45-64. As such, these values are not directly comparable. Worth 
noting, however, is that our study found quit readiness to be lowest in active smokers 
older than 65, followed very closely by the 18-25 age range, while quit intent was clearly 
lowest in the 18-25 age range. Considering both aspects of quit interest, it would seem 
that our findings differed from the results from the 2010 NHIS, with general quit interest 
lowest in 18-25 year olds. 
Analysis of the 2010 NHIS also yielded a link between health insurance and quit 
interest, suggesting that active smokers with private health insurance or Medicaid were 
more likely to be interested in those with Medicare or no health insurance. (CDC, 2011) 
Our study was unable to find a similar trend in the data we obtained. An analysis of quit 
interest among smokers with different healthcare coverage, presented in Table 9, 
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indicated that self-reported quit interest was lowest in those with private health insurance 
and no health insurance and highest in those with Medicare and Medicaid. 
Quit Attempts 
 The number of quit attempts reported by current and former smokers was 
presented in Table 10. Because our study looked at quit attempts ever made by smokers, 
our findings not directly comparable to the results from the 2010 NHIS, which reported 
that 52.4% of smokers reported making quit attempts in the previous year (CDC, 2011). 
Nevertheless, our findings confirm that current smokers are actively attempting to initiate 
tobacco cessation, with 75.1% of active smokers reporting that they had attempted to quit 
smoking  
Looking at reports of quit attempts among different age demographics, as shown 
in Table 11, it was found that of active smokers, those over 65 years of age had the 
largest proportion of those who had attempted to quit smoking more than once and the 
lowest found in the 18-25 age range. When also considering former smokers, the 41-64 
range reported the largest proportion of those who attempted to quit more than once and 
the lowest remaining the 18-25 range. These results seem to differ from the findings of 
the 2010 NHIS, which indicated that the ages of 18-24 were more actively attempting to 
initiate tobacco cessation. 
Our study did correlate with the trend found in the 2010 NHIS, which saw those 
with private health insurance or Medicaid more actively attempting tobacco cessation 
than those with no health plan (CDC, 2011). Analysis of our data, presented in Table 12, 
showed that study participants reporting some form of health insurance were more likely 
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to have attempted initiating tobacco cessation once or more. Our findings differed from 
their claim that those with private health insurance or Medicaid more actively attempted 
tobacco cessation than those with Medicare, however. Our data showed that 81.2% of 
smokers with Medicare attempted tobacco cessation more than once, a proportion greater 
than those with private health insurance (80.2%) and Medicaid (79.5%). 
Tobacco Cessation Aid Usage 
 In Table 13, we reported tobacco cessation usage among current and former 
smokers who took part in our study, finding that 30.7% of study participants had used 
some form of tobacco cessation aid in previous quit attempts. This value compares 
favorably to the findings of the 2010 NHIS, which reported that the use of tobacco 
cessation aids among current and former smokers was 31.7% (CDC, 2011).  
We also found that 69.3% of current and former smokers reported initiating quit 
attempts unassisted, or without the help of quit aids, which were highest among former 
smokers and lowest among daily smokers. These findings were not consistent with those 
found in other studies, which suggested that unassisted quit attempts among smokers had 
decreased to 50.3% (Edwards et al., 2014). 
Perceived Effect of Tobacco Cessation Aids 
 We presented the use of tobacco cessation aids by type of aid used by the 
participants that enrolled in our study in Table 16. Table 17 looked more closely at the 
2,306 study participants that reported using NRTs analyzing which nicotine replacements 
were more commonly used. We found that 979 subjects (9.5% of all participants) 
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reported using nicotine gum and 190 subjects (1.8% of all participants) reported using 
nicotine lozenges. Approximately 97% of these study participants gave an assessment of 
the effect of these products in helping them abstain from smoking, presented in Table 18.  
 According to a review of clinical nicotine replacement trials, nicotine replacement 
gum is associated with a relative risk for abstinence of 1.49 (95% CI = 1.40-1.60) and 
nicotine replacement lozenges are associated with a relative risk of 1.95 (95% CI = 1.61 
to 2.36). (Stead et al., 2012) Nicotine replacement gum is thought to be 1.49 times more 
likely to achieve abstinence than placebo or no cessation aid, and nicotine replacement 
lozenges are thought to be 1.95 times more likely to achieve abstinence. 
The results of our study did not show the overall positive response these figures 
might suggest. In fact, a majority of nicotine gum users (57.8%) thought that it was 
ineffective in aiding their tobacco cessation attempts, with only 30.1% responding 
favorably to nicotine gum use. Similarly, a majority of nicotine lozenge users (49.5%) 
thought that they were unhelpful in their quit attempts, with 38.7% of lozenge users 
responding favorably to its effect on their quit attempts. 
 It has been suggested that attempts to study tobacco cessation aid effectiveness in 
a population survey could be affected by a systematic bias, such as recall bias. A recent 
article studied the reports of quit attempts from those who used quit aids and those who 
attempted to initiate tobacco cessation unassisted. In comparing responses from the two 
groups, they found that those who used some form of quit aid on their most recent failed 
quit attempt reported that attempt as having started earlier than those who attempted to 
quit unassisted. The study said that this demonstrated the existence of a recall bias, 
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wherein quit attempts that featured the use of cessation aids were more often remembered 
than other failed quit attempts that were unassisted. The study also suggested that quit aid 
use was likely to be associated with higher consumption of tobacco products and 
increased addiction, affecting the potential for success and creating a bias against the 
effect that quit aid might have (Borland et al., 2012). 
In order to understand this within the context of our study, we looked at the 
perceived effect of nicotine replacement gums and lozenges as reported by daily, 
occasional, and former smokers. In both gums and lozenges, it appeared that former 
smokers, those who had successfully achieved abstinence using cessation aids, were more 
likely to report that the cessation aid was useful compared to current smokers who used 
that same product. Active daily smokers were, in fact, more likely to report that the 
nicotine replacement products were not useful. The reported effect of nicotine 
replacement gum and current tobacco use showed a weak but statistically significant 
relationship (V=0.124, p < 0.05) that could support these observations. We could not 
accurately calculate the Cramer’s V for the relationship between the reported effect of 
nicotine replacement lozenges and current tobacco use due to the smaller sample size, but 
the statistical significance of the relationship between these two variables was confirmed 
with a chi-square test which yielded a p < 0.05. This analysis is presented in Table 20. 
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Table 20: Perceived effectiveness of NRT products by current tobacco use frequency 
	  
Current Tobacco Use 
Effect of NRT - Gum Every day Some days Not at all 
Useful (6-10) 121 (23.8%) 40 (32.8%) 125 (39.1%) 
Not Sure (5) 54 (10.6%) 19 (15.6%) 42 (13.1%) 
Not Useful (1-4) 333 (65.6%) 63 (51.6%) 153 (47.8%) 
Cramer's V: 0.124, approximate significance: p < 0.05 
	  
Current Tobacco Use 
Effect of NRT- Lozenges Every day Some days Not at all 
Useful (6-10) 35 (31.3%) 6 (33.3%) 72 (42.9%) 
Not Sure (5) 13 (11.6%) 5 (27.8%) 4 (2.4%) 
Not Useful (1-4) 64 (57.1%) 7 (38.9%) 92 (54.7%) 
Chi-square = 22.0, approximate significance: p < 0.001 
   While this comparison did not confirm the possibility of recall bias within our 
study, the trend found among former smokers rating the effect of cessation aid use more 
favorably in comparison to current smokers prompted us to explore this further. We 
attempted to compare reported effect of nicotine replacement gum and lozenges with 
consumption of cigarettes (a measure of nicotine addiction), but found no significant 
relationship between these variables (p > 0.05) and no trends could be seen 
observationally. Without an associated trend with nicotine addiction, we weren’t able to 
further explore the possibility of recall bias suggested by Borland et al. 
Limitations of this Study 
 While we were unable to provide evidence for or against the presence of recall 
bias in our study, we recognize the potential systemic biases that might be inherent in 
cross-sectional studies such as this one. Response bias and nonresponse bias are two such 
biases. In introducing exclusion criteria, we recognize that we could have excluded 
valuable responses, particularly in patients who may have been excluded from the study 
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due to airway treatments, possible indicators of the respiratory problems associated with 
chronic tobacco use and smoking. Ultimately, however, we do not believe that 
nonresponse within the population available to us was a significant problem in our study, 
as our response rate was sufficiently high, with 64% of those approached eligible for 
enrollment and 94% of eligible patients and visitors enrolled in our study.  
 Our survey relied on study participants to accurately report their current tobacco 
use and frequency of smoking. These responses were not validated by any biochemical 
testing, such as analyzing serum cotinine levels. As such, this could have introduced 
some response bias into the outcome of the survey. Studies have shown that serum 
cotinine levels correlate fairly well with self-reported smoking status, however, with one 
study suggesting a discrepancy as little as 2.5-2.7% (Vartiainen et al., 2002). As such, we 
do not feel that response bias had a significant impact on the outcome of our study, given 
the method and delivery of our survey, but we recognize that we did not test or adjust for 
this bias during the course of the study.  
 Our study used a prompt to elicit responses from our study participants. In setting 
up the study in this way, we had to establish some definitions that, while the correct 
choices for the context of our survey, limited the comparability of our study to other 
survey findings. This was most notable in the comparisons of our data to that of the 2010 
NHIS findings, where age categories, our expanded look at markers of quit interest (quit 
readiness and intent to quit), as opposed to a singular concept of quit interest, and our 
focus on quit attempts over the course of tobacco use, as opposed to within the past few 
years, made direct comparisons difficult. 
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 The location in which our study was conducted and the subsequent population 
that we enrolled into the study might have affected how our findings compared to other 
sources, as well. The NHIS was conducted by pre-selecting a representative sample of 
households nationwide and then approaching this population for enrollment. Our study 
was conducted in the Emergency Departments of ten different hospitals nationwide and 
no population-based pre-screening or pre-selecting was done before approaching or 
enrolling patients and visitors into our study. As such, our population might have been 
skewed toward those that might be more inclined to visit the emergency department and 
certain variables, such as health insurance, would differ accordingly.5 
Unfortunately, the scope of our study was limited by technological problems. 
During the transition from the online REDCap™ database to our analytical software 
SPSS, an error associated with the export process lead to the unrecoverable loss of 
responses to certain tobacco variable questions. While the extent of this loss was 
relatively small, the variables affected included the perceived effectiveness of tobacco 
cessation aids, including the nicotine patch, tobacco cessation pills, and counseling-based 
cessation aids. Without these responses, we had to alter the focus of our study 
accordingly, in order to utilize and analyze the responses that were unaffected by the 
error affecting the export process. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 In 2012, the census bureau reported that 63.9% of Americans had private health insurance, 
15.7% were covered by Medicare, and 15.4% were uninsured. (Pear, 2013.) In our study, for 




Our findings did not always correspond with national tobacco surveys. Notably, 
the results of our study indicated that active smokers that reported smoking less 
(indicating only smoking on some days or reporting fewer cigarettes smoked per day) 
were more likely to express interest, described by their readiness and intent to initiate 
tobacco cessation, than those that reported smoking more or more frequently. This 
interest appeared lowest in the youngest age demographic, 18-25 year olds, who also 
reported the lowest proportion of quit attempts.  In addition, while our study provided a 
comparable report of quit aid use, it found that unassisted quit attempts were reported to 
be higher than in other population survey studies. Quit aid use was increased with 
increased quit attempts and the efficacy of these quit aids was generally reported higher 
by those who had successfully quit smoking than those who actively smoked. 
In light of the differences in our study and the limitations we encountered 
throughout, further study needs to be conducted to better understand the perceived effect 
of tobacco cessation aids and to pinpoint this disconnect with the efficacy reported from 
clinical trials. In order to make findings more comparable to other national tobacco 
surveys, future studies should be designed around clear and common definitions for 
categorizing details, such as age, active tobacco use, and quit interest. A focus on quit 
attempts should be modulated by some measure of recency, (e.g., asking for quit attempts 
made within the previous year or two years, rather than “ever made”) in order to make 
findings comparable to other sources. 
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